{"id":"W2891694121","doi":"10.1200/jco.2017.35.15_suppl.9522","title":"Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Cohort; Expanded access; Oncology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001410197,0.0003975567,0.0004886271,0.0003940058,0.0001758872,0.000583492,0.0003812939,0.0004287202,0.001999083],"category_scores_gemma":[0.001034971,0.0001641679,0.001086625,0.0004072122,0.0002474251,0.0004913199,0.0004995589,0.0009975976,0.0002020784],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007906687,"about_ca_system_score_gemma":0.0006232006,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009065152,"about_ca_topic_score_gemma":0.002047901,"domain_scores_codex":[0.9994854,0.0002181757,0.00002895251,0.0001331131,0.00007325386,0.00006104325],"domain_scores_gemma":[0.9990472,0.0002647876,0.0002628729,0.00008498312,0.00005272084,0.0002873982],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5294442,0.009034328,0.2795759,0.0008478807,0.004738297,0.0004310526,0.0002302631,0.006651286,0.01624933,0.0002921631,0.0113337,0.1411717],"study_design_scores_gemma":[0.05045394,0.1932217,0.728277,0.0001290275,0.005290294,0.0009748671,0.0001160342,0.008425181,0.004468797,0.0003605939,0.008233133,0.0000492648],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954851,0.0007841696,0.0002482095,0.00009921601,0.00001711826,0.0001663312,0.002031107,0.00002911914,0.001139662],"genre_scores_gemma":[0.9948567,0.0002322749,0.0002793968,0.0001750691,0.00004199127,0.0001931409,0.003668095,0.000008732377,0.0005445892],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001999083,"threshold_uncertainty_score":0.007457972,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0642788692201449,"score_gpt":0.4571803772239324,"score_spread":0.3929015080037875,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}